NIH Licensing Forum: COVID-19 Vaccines - A Conversation with NIAID's Amy Petrik, LES 2021 'Deal of Distinction' Winner

December 21, 2021

NIH Licensing Forum: COVID-19 Vaccines - A Conversation with NIAID's Amy Petrik, LES 2021 'Deal of Distinction' Winner

Join us on December 7th at 2 pm for the Tuesday Licensing Forum's discussion with Amy Petrik, PhD, of NIAID's Technology Transfer Intellectual Property Office (TTIPO) regarding the exciting licensing agreements that led to the world's first FDA approved vaccine for COVID-19. The LES Deals of Distinction Awards are given each year to recognize major business transactions involving licensing that exemplify best practices and creativity to achieve strategic business objectives that have a significant impact on advancing innovation.

The LES awards this year focused on COVID-19 vaccines, and the various vaccine agreements negotiated this past year by Amy Petrik were recognized by LES as one this year's top awards in licensing. The award also spotlighted the key role that licensing and technology transfer played in responding to the pandemic. The path towards developing the first FDA-approved COVID-19 vaccine was cleared by a research collaboration between scientists at the NIAID's Vaccine Research Center, the Scripps Research Institute, Dartmouth College and the University of Texas-Austin – all subject to inter-institutional agreements (IIAs) completed by NIAID. The nonexclusive patent license of the stabilized spike protein discovery from those collaborations to BioNTech and with that company's subsequent partnership with Pfizer produced an mRNA-based vaccine launched in 2020 that has been administered now hundreds of millions of times.

Amy Petrik earned her doctoral degree in chemistry at the University of Maryland, College Park and trained as a postdoctoral fellow at NIAMS before starting a technology transfer fellowship at the (then) NIAID Office of Technology Development in 2013. Since 2014 she has worked as a Technology Transfer and Patent Specialist at NIAID where she has managed a portfolio the includes mainly vaccine and monoclonal antibody technologies.

Here are the call-in & WebEx details for the Tuesday Licensing Forum:

2:00 p.m. | Eastern Daylight Time (New York, GMT-04:00) | 1 hr 30 mins

Meeting number (access code): 2550 971 1720

Meeting password: P38Ad2DBnQb

Join by phone: 1-650-479-3208 Call-in toll number (US/Canada)